SESN
Sesen Bio Inc.
Halal Rating :
Last Price
$0.45
Last updated:
Market Cap
-
7D Change
2.92%
1 Year Change
-81.6%
Company Overview
Exchange
Next Earnings Date
Sesen Bio Inc. was a biopharmaceutical company focused on developing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's lead product candidate was Vicineum, a protein therapeutic candidate for non-muscle invasive bladder cancer (NMIBC). However, in March 2024, the company completed its merger with Alyvant Holdings and changed its name to Alyvant.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $3.38m | $16.53m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $9.2m | $20.87m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $3.4m | $22.91m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Sesen Bio Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.